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Background
The efficacy and safety of anticoagulant treatment for patients with acute, symptom-
atic superficial-vein thrombosis in the legs, but without concomitant deep-vein 
thrombosis or symptomatic pulmonary embolism at presentation, have not been es-
tablished.
Methods
In a randomized, double-blind trial, we assigned 3002 patients to receive either fonda-
parinux, administered subcutaneously at a dose of 2.5 mg once daily, or placebo for 
45 days. The primary efficacy outcome was a composite of death from any cause or 
symptomatic pulmonary embolism, symptomatic deep-vein thrombosis, or symp-
tomatic extension to the saphenofemoral junction or symptomatic recurrence of 
superficial-vein thrombosis at day 47. The main safety outcome was major bleeding. 
The patients were followed until day 77.
Results
The primary efficacy outcome occurred in 13 of 1502 patients (0.9%) in the fonda-
parinux group and 88 of 1500 patients (5.9%) in the placebo group (relative risk 
reduction with fondaparinux, 85%; 95% confidence interval [CI], 74 to 92; P<0.001). 
The incidence of each component of the primary efficacy outcome was significantly 
reduced in the fondaparinux group as compared with the placebo group, except for 
the outcome of death (0.1% in both groups). The rate of pulmonary embolism or 
deep-vein thrombosis was 85% lower in the fondaparinux group than in the pla-
cebo group (0.2% vs. 1.3%; 95% CI, 50 to 95; P<0.001). Similar risk reductions were 
observed at day 77. A total of 88 patients would need to be treated to prevent one 
instance of pulmonary embolism or deep-vein thrombosis. Major bleeding occurred 
in one patient in each group. The incidence of serious adverse events was 0.7% with 
fondaparinux and 1.1% with placebo.
Conclusions
Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treat-
ment of patients with acute, symptomatic superficial-vein thrombosis of the legs 
and did not have serious side effects. (Funded by GlaxoSmithKline; ClinicalTrials 
.gov number, NCT00443053.)
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Superficial-vein thrombosis of the legs is a common condition,1,2 with an es-timated incidence that may exceed that of 
deep-vein thrombosis.3,4 Patients with isolated su-
perficial-vein thrombosis — that is, without con-
comitant deep-vein thrombosis or symptomatic 
pulmonary embolism at presentation — are at risk 
for subsequent symptomatic venous thromboem-
bolic complications.1-7 In a large, prospective, ob-
servational study, the 3-month risk of such com-
plications was 8.3%, with a 3.3% risk of deep-vein 
thrombosis or pulmonary embolism.8
The treatment of this disease has not been 
adequately addressed in randomized trials. Ac-
cordingly, the recommendations in various guide-
lines are weak, and in practice, therapeutic strate-
gies vary, ranging from no treatment to the use 
of antiinflammatory agents or anticoagulant drugs 
or surgery.8-14 The few randomized studies that 
have been performed did not clarify the circum-
stances under which surgery is required or the 
value or optimal dose and duration of anticoagu-
lant or antiinflammatory therapy.6,15-19 The results 
of the two largest studies, evaluating low-molecu-
lar-weight heparin, suggest that high-dose (ther-
apeutic) or intermediate-dose regimens do not 
provide substantial benefits over low-dose (pro-
phylactic) regimens and that a treatment period 
of 12 days or of 30 days is too short, with most 
symptomatic thromboembolic complications oc-
curring after the treatment period.6,17 None of 
the published studies showed a clinically rele-
vant bene fit of any treatment as compared with 
placebo.6,7 Thus, the aim of our study was to 
determine whether there is a well-defined treat-
ment that could provide a benefit.
We conducted the Comparison of Arixtra in 
Lower Limb Superficial Vein Thrombosis with 
Placebo (CALISTO) trial to evaluate the efficacy 
and safety of fondaparinux, a specific factor Xa 
inhibitor, in reducing symptomatic venous throm-
boembolic complications or death from any cause 
in patients with acute, isolated superficial-vein 
thrombosis of the legs. For the active treatment, 
we selected the prophylactic dose of 2.5 mg of 
fondaparinux once daily, because this dose has 
been shown to be reasonably effective and to have 
an acceptable side-effect and adverse-event pro-
file in a broad range of conditions.20-23 Treatment 
was to be administered for 45 days.
Me thods
Patients
Hospitalized or nonhospitalized patients 18 years 
of age or older, with acute, symptomatic lower-
limb superficial-vein thrombosis at least 5 cm long, 
as confirmed by standardized compression ultra-
sonography, were eligible to undergo randomiza-
tion. Patients were excluded if the interval between 
the onset of their symptoms and planned random-
ization was more than 3 weeks; if they had been 
treated for cancer within the previous 6 months; 
if they presented with symptomatic or asymptom-
atic deep-vein thrombosis, symptomatic docu-
mented pulmonary embolism, or superficial-vein 
thrombosis associated with sclerotherapy or place-
ment of an intravenous catheter or located within 
3 cm of the saphenofemoral junction; or if they had 
a documented history of superficial-vein throm-
bosis within the previous 3 months or deep-vein 
thrombosis or pulmonary embolism within the 
previous 6 months. Patients were also excluded 
from randomization if they had received an anti-
thrombotic agent for more than 48 hours (other 
than aspirin at a dose ≤325 mg per day) or a non-
steroidal antiinflammatory drug for more than 
72 hours as treatment for the current episode of 
superficial-vein thrombosis or if, in the investiga-
tor’s opinion, they required ligation of the sa-
phenofemoral junction or stripping of varicose 
veins. Other exclusion criteria were major surgery 
within the previous 3 months and conditions that 
could confer a predisposition to bleeding, includ-
ing severe hepatic impairment, a creatinine clear-
ance of less than 30 ml per minute, and a platelet 
count of less than 100,000 per cubic millimeter. 
Finally, women of childbearing age were excluded 
if they were pregnant or were not using a reliable 
contraceptive method.
Study Design
This trial was an international, multicenter, ran-
domized, double-blind, placebo-controlled study; 
the protocol, including the statistical analysis plan, 
is available with the full text of this article at 
NEJM.org. With the use of a central telephone sys-
tem and a computer-generated randomization list, 
consecutive patients were randomly assigned, in 
a 1:1 ratio, to fondaparinux at a dose of 2.5 mg or 
matching placebo, administered subcutaneously 
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once daily for 45 days. Randomization was per-
formed in blocks of four without any stratifica-
tion. The maximum interval allowed between the 
qualifying ultrasonographic study and random-
ization was 48 hours. The day of randomization 
was defined as day 1. Follow-up visits were sched-
uled at days 10±2, 30±2, 45±2, and 75±2. No rou-
tine ultrasonographic examinations were required 
during the follow-up period. The study was con-
ducted according to the ethical principles stated 
in the Declaration of Helsinki and local regula-
tions. The protocol was approved by an indepen-
dent ethics committee, and written informed 
consent was obtained from all patients before they 
underwent randomization.
The study was funded by GlaxoSmithKline. 
A steering committee, including one nonvoting 
member representing the sponsor, was responsi-
ble for the design, conduct, and reporting of the 
study. Data were collected and analyzed by the 
study sponsor. The database of adjudicated out-
comes was managed by an independent central 
adjudication committee. The members of the writ-
ing committee wrote the first draft of the manu-
script and made the decision to submit the manu-
script for publication. All the authors contributed 
to the writing of subsequent drafts of the manu-
script, had full access to the data and analyses, 
and vouch for the accuracy and completeness of 
the report, as well as the fidelity of the study to the 
protocol and statistical analysis plan.
Study Drugs
Fondaparinux and placebo were packaged in iden-
tical boxes containing visually identical, prefilled 
0.5-ml single-dose syringes. Each patient received 
one box containing 45 single-dose syringes (1 per 
day for 45 days) of either 2.5 mg of fondaparinux 
sodium (Arixtra, GlaxoSmithKline) or placebo (so-
dium chloride). At the time of randomization, pa-
tients were provided with an injection diary. The 
investigators were encouraged to teach the patients 
to administer the study drugs themselves, but the 
final decision about self-administration was left 
to the investigator’s discretion.
Patients were encouraged to use graduated 
compression stockings and were allowed to take 
acetaminophen or topical nonsteroidal antiinflam-
matory drugs as needed. The use of oral antiplate-
let agents or aspirin at a low dose (≤325 mg per 
day) was discouraged. Concomitant treatment with 
dextran, thrombolytic agents, any other anticoagu-
lant agent, more than one antiplatelet agent, as-
pirin at doses higher than 325 mg per day, gly-
coprotein IIb/IIIa inhibitors, oral nonsteroidal 
antiinflammatory drugs, or topical heparins or 
heparinoids was prohibited throughout the course 
of the study.
Outcome Measures
The primary efficacy outcome was the composite 
of death from any cause, symptomatic pulmonary 
embolism (confirmed by ventilation–perfusion 
scanning, helical computed tomography, pulmo-
nary angiography, or autopsy), symptomatic deep-
vein thrombosis (confirmed by ultrasonography 
or venography), or symptomatic extension to the 
saphenofemoral junction or symptomatic recur-
rence of superficial-vein thrombosis (confirmed 
by ultrasonography) up to day 47. (For definitions 
of recurrence and extension of superficial-vein 
thrombosis, see the Supplementary Appendix, 
available at NEJM.org.) Secondary efficacy out-
comes were the composite primary efficacy out-
come up to day 77 and the following outcomes up 
to day 47 and day 77: each component of the pri-
mary efficacy outcome, the composite of symptom-
atic pulmonary embolism or deep-vein thrombo-
sis, and surgery for superficial-vein thrombosis.
Analyses of safety outcomes were performed 
with data obtained until day 47 or until 4 days 
after the last injection of the study drug (which-
ever was longer), with data obtained until 4 days 
after the last injection of the study treatment (on-
treatment analysis), and with data obtained until 
day 77. The main safety outcome was major bleed-
ing. Other safety outcomes were clinically rele-
vant nonmajor, minor, and total (any) bleeding 
(definitions provided in the Supplementary Ap-
pendix) and arterial thromboembolic events. All 
other adverse events that occurred while the pa-
tient was receiving treatment were reported.
If a thromboembolic or bleeding complication 
occurred during the course of the study, manage-
ment of the condition was left to the investiga-
tor’s discretion. All symptomatic outcomes were 
reviewed by the central adjudication committee, 
whose members were unaware of the patients’ 
group assignments. Patient safety was monitored 
by an independent data and safety monitoring 
committee.
Statistical Analysis
We estimated that with a sample of 1250 patients 
in each group, the study would have at least 98% 
power to detect a 50% reduction in the rate of the 
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primary efficacy outcome, assuming an incidence 
of the primary efficacy outcome of 8.0% in the 
placebo group,6,8,17 at a two-sided 5% level of sig-
nificance. As planned, the independent steering 
committee, whose members were unaware of the 
group assignments, monitored the overall event 
rate for the primary efficacy outcome. On No-
vember 5, 2008, on the basis of an observed rate of 
the primary efficacy outcome of 3.1%, the com-
mittee decided to increase the sample to 3000 pa-
tients in order to preserve at least 90% power to 
detect a 50% reduction in the rate of the primary 
efficacy outcome in the fondaparinux group.
Efficacy analyses were performed on data from 
the intention-to-treat population, which included 
all the patients who had undergone randomiza-
tion. Patients for whom a primary efficacy assess-
ment was lacking (i.e., those with no events and 
no information on their status with respect to ef-
ficacy at day 45±2) were assumed not to have had 
any event. Safety analyses were performed on data 
from the as-treated population, which comprised 
all patients who had undergone randomization 
and who had received at least one dose of the 
study drug.
A two-sided Fisher’s exact test at the 5% sig-
nificance level was performed for efficacy evalu-
ations, and the resulting P values are reported. 
Absolute differences and relative risks, with 95% 
confidence intervals, are also reported. Time-to-
event outcomes estimated by means of the Kap-
lan–Meier method were compared with the use 
of the log-rank test. A prespecified sensitivity 
analysis was performed in which patients with 
missing data on the primary efficacy outcome 
were excluded. Zelen’s exact test was used to verify 
the consistency of the treatment effect across 16 
prespecified sets of subgroups and 1 set of sub-
groups that was defined post hoc.24
R esult s
Study Populations and Treatments
Between March 2007 and May 2009, a total of 
3002 patients were enrolled at 171 centers in 17 
countries (see the Supplementary Appendix) — 
1502 in the fondaparinux group and 1500 in the 
placebo group. Of the 3002 patients who under-
went randomization, 18 patients in the fonda-
parinux group (1.2%) and 22 in the placebo group 
(1.5%) did not have a primary efficacy assessment 
(Table 1 in the Supplementary Appendix). Overall, 
1481 patients in the fondaparinux group (98.6%) 
and 1467 in the placebo group (97.8%) completed 
the follow-up visit at day 75±2 (Table 2 in the Sup-
plementary Appendix). Of the 3002 patients who 
underwent randomization, 4 patients in the fonda-
parinux group and 11 in the placebo group re-
ceived no study drug (as a result of the patient’s 
decision, in each case), and 1 patient who was ran-
domly assigned to the placebo group received at 
least one dose of fondaparinux in error; thus, 1499 
patients in the fondaparinux group (99.8%) and 
1488 in placebo group (99.2%) were included in 
the safety analyses.
The demographic and clinical characteristics of 
the patients, the medications and interventions 
the patients received before their entry into the 
study (Table 1, and Table 3 in the Supplementary 
Appendix), the duration of treatment, and the ad-
herence to treatment, as calculated with the use 
of a formula that was based on the number of 
syringes used and the number returned unused 
(Table 2), were well balanced between the two 
groups. In addition, the treatments other than the 
study drugs that patients received during the 
course of the study were well balanced between 
the two groups, with two exceptions: patients in 
the placebo group received anticoagulant drugs or 
oral nonsteroidal antiinflammatory drugs more 
frequently than did patients in the fondaparinux 
group (Table 2).
Efficacy Outcomes
The primary efficacy outcome occurred in 13 of 
1502 patients (0.9%) in the fondaparinux group 
and 88 of 1500 patients (5.9%) in the placebo group 
(relative risk with fondaparinux, 0.15; 95% confi-
dence interval [CI], 0.08 to 0.26; P<0.001; num-
ber needed to treat, 20) (Table 3). This result was 
confirmed in the sensitivity analysis in which pa-
tients with a missing primary efficacy assessment 
were excluded (data not shown). The incidence of 
each component of the primary efficacy outcome 
was significantly reduced in the fondaparinux 
group as compared with the placebo group (includ-
ing the incidence of pulmonary embolism [num-
ber needed to treat to prevent one pulmonary 
embolism was 300]), except for the incidence of 
death, which did not differ significantly between 
the two groups. The risk of the composite of deep-
vein thrombosis or pulmonary embolism was re-
duced by 85% with fondaparinux as compared 
with placebo (0.2% [3 of 1502 patients] vs. 1.3% 
[20 of 1500 patients]; P<0.001; number needed to 
treat, 88). All the efficacy results were main-
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tained at day 77 (Fig. 1 and Table 3). The treatment 
effect was consistent across all the subgroups we 
examined (Fig. 2). Finally, more patients in the pla-
cebo group than in the fondaparinux group un-
derwent surgery for superficial-vein thrombosis 
(Table 3), including ligation of the saphenofemo-
ral junction, which by day 77 had been performed 
in 52 patients in the placebo group (3.5%), as com-
pared with 8 in the fondaparinux group (0.5%).
Safety Outcomes
By day 47, major bleeding had occurred in one 
patient (0.1%) in each group (P = 1.00). The rates 
of clinically relevant nonmajor, minor, and total 
Table 1. Baseline Characteristics of the Study Patients.*
Characteristic
Fondaparinux 
(N = 1502)
Placebo  
(N = 1500) P Value†
Age — yr 57.1±13.3 56.9±13.6 0.69
Female sex — no. (%) 974 (64.8) 944 (62.9) 0.29
Body-mass index‡
Mean 29.2±5.2 29.0±5.4 0.32
≥30 — no. (%) 574 (38.2) 536 (35.7) 0.16
Medical conditions — no. (%)
Varicose veins 1331 (88.6) 1329 (88.6) 1.00
Previous superficial-vein thrombosis 178 (11.9) 178 (11.9) 1.00
Previous deep-vein thrombosis or pulmonary embolism 105 (7.0) 104 (6.9) 1.00
Cardiovascular disease§ 71 (4.7) 66 (4.4) 0.73
Heart failure or respiratory failure
Chronic 71 (4.7) 88 (5.9) 0.17
Acute¶ 5 (0.3) 1 (0.1) 0.22
Known thrombophilia 20 (1.3) 18 (1.2) 0.87
Autoimmune disease 12 (0.8) 14 (0.9) 0.70
Acute infectious disease¶ 11 (0.7) 8 (0.5) 0.65
History of cancer 32 (2.1) 29 (1.9) 0.80
Current hospitalization 10 (0.7) 11 (0.7) 0.83
Trauma¶ 10 (0.7) 16 (1.1) 0.25
Treatment at inclusion — no. (%)
Graduated compression stockings 1131 (75.3) 1147 (76.5) 0.47
Analgesic agents 391 (26.0) 401 (26.7) 0.68
Topical nonsteroidal antiinflammatory drugs 598 (39.8) 608 (40.5) 0.71
Topical anticoagulant drugs 57 (3.8) 50 (3.3) 0.55
Oral nonsteroidal antiinflammatory drugs or COX-2 inhibitors 54 (3.6) 65 (4.3) 0.31
Oral or parenteral anticoagulant drugs 67 (4.5) 58 (3.9) 0.46
Aspirin or other antiplatelet agents 347 (23.1) 364 (24.3) 0.47
Glucocorticoids 34 (2.3) 25 (1.7) 0.29
Oral contraceptive or hormone-replacement therapy 43 (2.9) 40 (2.7) 0.82
* Plus–minus values are means ±SD.
† The P values were calculated with the use of Student’s t-test for continuous variables and Fisher’s exact test for cate-
gorical variables.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Cardiovascular disease includes myocardial infarction, ischemic stroke, and peripheral arterial occlusive disorder.
¶ Data are shown for patients in whom the condition was present at baseline or had occurred within the previous  
4 weeks.
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bleeding and arterial thromboembolic complica-
tions did not differ significantly between the two 
groups (Table 4). Safety results were similar in 
on-treatment analyses and in analyses at day 77 
(Table 4 in the Supplementary Appendix). There 
were no clinically relevant between-group differ-
ences in the incidence of any other adverse events 
(Table 5 and Table 6 in the Supplementary Appen-
dix). The only serious adverse event that was re-
ported in more than one patient in either study 
group was coronary artery disease, which was re-
ported in two patients in the placebo group (0.1%). 
No episodes of thrombocytopenia were reported 
in the fondaparinux group.
Discussion
In this study, we investigated the effect of antico-
agulant therapy as compared with placebo on 
symptomatic outcomes in patients with isolated 
superficial-vein thrombosis. Treatment with fonda-
parinux at a dose of 2.5 mg once daily for 45 days, 
as compared with placebo, resulted in an absolute 
risk reduction of 5 percentage points — which 
Table 2. Treatment Received during the Study.*
Treatment
Fondaparinux  
(N = 1502)
Placebo  
(N = 1500)
Study treatment
Receipt of at least one injection of study drug — no. (%) 1499 (99.8) 1488 (99.2)
Mean days of treatment 43.6±7.3 41.2±11.0
Duration of treatment — no./total no. (%)
≤10 days 35/1499 (2.3) 95/1488 (6.4)
11–30 days 26/1499 (1.7) 66/1488 (4.4)
31–45 days 1161/1499 (77.5) 1091/1488 (73.3)
>45 days 277/1499 (18.5) 236/1488 (15.9)
Self-administered treatment — no. (%) 1360/1499 (90.7) 1364/1488 (91.7)
Adherence to treatment
Patients who adhered — no. (%)† 1434 (95.5) 1329 (88.6)
Mean adherence — %‡ 98.3±8.9 98.4±8.7
Other treatments
Graduated compression stockings — no. (%) 1247 (83.0) 1247 (83.1)
Analgesic agents — no. (%) 416 (27.7) 428 (28.5)
Topical nonsteroidal antiinflammatory drugs — no. (%) 623 (41.5) 627 (41.8)
Topical anticoagulant drugs — no. (%) 59 (3.9) 50 (3.3)
Oral nonsteroidal antiinflammatory drugs or COX-2 inhibitors — no. (%) 32 (2.1) 56 (3.7)
Oral or parenteral anticoagulant treatment — no. (%)§ 17 (1.1) 96 (6.4)
High (therapeutic) dose 10 (0.7) 62 (4.1)
Intermediate dose 1 (0.1) 6 (0.4)
Low (prophylactic) dose 6 (0.4) 44 (2.9)
Unknown dose 2 (0.1) 3 (0.2)
Aspirin or other antiplatelet agents — no. (%) 322 (21.4) 339 (22.6)
* Plus–minus values are means ±SD.
† Patients were considered not to have adhered to treatment if they received less than 80% of the scheduled study drug 
(i.e., <36 injections) or if the last day of treatment was before day 40. This included patients who discontinued treat-
ment owing to an adverse event or a lack of efficacy.
‡ Mean adherence was calculated with the use of the following formula: [(number of syringes dispensed − number of  
syringes returned − number of syringes lost or not returned and not used) ÷ total number of days of treatment] × 100.
§ Patients could have received more than one anticoagulant treatment; different treatments might have been dispensed 
with the use of different dosage regimens (therapeutic, intermediate, or prophylactic).
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was equivalent to an 85% reduction in the risk of 
symptomatic thromboembolic complications or 
death — without increasing the incidence of bleed-
ing. The number needed to treat to prevent one 
event of the primary efficacy outcome was 20, 
whereas the number needed to treat to prevent 
deep-vein thromboembolism or a pulmonary em-
bolism was 88. The study was placebo-controlled, 
since no standard treatment has been established 
in this clinical setting.7,9 This design was consid-
ered to be ethical, since all the patients benefited 
from close clinical monitoring, with adequate di-
agnostic procedures performed in the event of new 
or persistent symptoms, and since an independent 
data and safety monitoring committee carefully 
oversaw the study outcomes.
The patients in our study are representative of 
those encountered in routine practice1,2,8: almost 
all were outpatients, and there was a clear pre-
dominance of women and a substantial proportion 
of obese patients, most presenting with varicose 
veins and superficial-vein thrombosis involving 
the great saphenous vein. The rate of symptom-
atic thromboembolic complications in the place-
bo group at day 47 (5.9%; 95% CI, 4.7 to 7.2) was 
in the low range of the expected rate of throm-
boembolic events, possibly because very-high-risk 
patients (e.g., those with active cancer or a recent 
history of venous thromboembolism and those in 
whom the thrombus was located within 3 cm of 
the saphenofemoral junction) were not enrolled in 
this placebo-controlled trial. However, this rate 
and the corresponding rate at day 77 (6.3%; 95% 
CI, 5.1 to 7.6) are consistent with that observed at 
3 months in a prospective observational study in 
which a similar composite outcome was evaluated 
Table 3. Efficacy Outcomes.
Efficacy Outcome
Fondaparinux
(N = 1502)
Placebo 
(N = 1500)
Absolute Risk Reduction 
with Fondaparinux
Relative Risk with 
Fondaparinux P Value*
no. with event (%) percentage points (95% CI) % (95% CI)
By Day 47
Primary composite outcome† 13 (0.9) 88 (5.9) −5.0 (−6.3 to −3.7) 0.15 (0.08 to 0.26) <0.001
Death‡ 2 (0.1) 1 (0.1) 0.1 (−0.2 to 0.3) 1.99 (0.18 to 21.87) 1.00
Pulmonary embolism§ 0 5 (0.3) −0.3 (−0.6 to 0.0) Not calculated 0.03
Deep-vein thrombosis¶ 3 (0.2) 18 (1.2) −1.0 (−1.6 to −0.4) 0.17 (0.05 to 0.56) <0.001
Extension of superficial-vein thrombosis to 
the saphenofemoral junction
4 (0.3) 51 (3.4) −3.1 (−4.1 to −2.2) 0.08 (0.03 to 0.22) <0.001
Recurrence of superficial-vein thrombosis 5 (0.3) 24 (1.6) −1.3 (−2.0 to −0.6) 0.21 (0.08 to 0.54) <0.001
Deep-vein thrombosis or pulmonary embolism 3 (0.2) 20 (1.3) −1.1 (−1.8 to −0.5) 0.15 (0.05 to 0.50) <0.001
Surgery for superficial-vein thrombosis 11 (0.7) 57 (3.8) −3.1 (−4.1 to −2.0) 0.19 (0.10 to 0.37) <0.001
By Day 77
Composite outcome† 18 (1.2) 94 (6.3) −5.1 (−6.4 to −3.7) 0.19 (0.12 to 0.32) <0.001
Death‡ 2 (0.1) 1 (0.1) 0.1 (−0.2 to 0.3) 1.99 (0.18 to 21.87) 1.00
Pulmonary embolism§ 0 6 (0.4) −0.4 (−0.7 to −0.1) Not calculated 0.02
Deep-vein thrombosis 4 (0.3) 19 (1.3) −1.0 (−1.6 to −0.4) 0.21 (0.07 to 0.62) 0.001
Extension of superficial-vein thrombosis to 
the saphenofemoral junction
5 (0.3) 54 (3.6) −3.3 (−4.3 to −2.3) 0.09 (0.04 to 0.23) <0.001
Recurrence of superficial-vein thrombosis 8 (0.5) 26 (1.7) −1.2 (−2.0 to −0.4) 0.31 (0.14 to 0.68) 0.002
Deep-vein thrombosis or pulmonary embolism 4 (0.3) 22 (1.5) −1.2 (−1.9 to −0.5) 0.18 (0.06 to 0.53) <0.001
Surgery for superficial-vein thrombosis 15 (1.0) 61 (4.1) −3.1 (−4.2 to −1.9) 0.25 (0.14 to 0.43) <0.001
* P values were calculated with the use of Fisher’s exact test.
† Some patients had more than one event.
‡ There were two deaths from cancer in the fondaparinux group and one death from acute heart failure in the placebo group.
§  No instance of pulmonary embolism was fatal.
¶ There were 11 cases of proximal deep-vein thrombosis: 1 in the fondaparinux group and 10 in the placebo group.
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(8.3%; 95% CI, 6.0 to 10.6),8 confirming that su-
perficial-vein thrombosis is not a benign disease.
The relative reduction of 85% in the risk of 
symptomatic events that we observed with 2.5 mg 
of fondaparinux daily as compared with placebo 
is consistent with the reduction in the risk of 
venous thromboembolic complications that has 
been observed in studies evaluating anticoagu-
lant agents as compared with placebo or no ther-
apy for prophylaxis25-28 or treatment29 of venous 
thromboembolism. This benefit was evident with-
in the first days after treatment was initiated 
(Fig. 1), supporting the adequacy of the prophy-
lactic dose of 2.5 mg of fondaparinux and in 
accord with the substantial efficacy data already 
available with respect to a dose of 2.5 mg of fonda-
parinux in various clinical settings.20-23 We chose 
a 45-day duration of treatment with the specific 
objective of avoiding the “catch-up” phenomenon 
observed with shorter (up to 30-day) courses of 
low-molecular-weight heparin.6,17 This objective 
was met, since the efficacy of fondaparinux ef-
ficacy was maintained through day 77.
As compared with placebo, fondaparinux also 
significantly reduced, by the same magnitude, the 
risk of each thromboembolic component of the 
primary efficacy outcome and was associated with 
a clinically important and statistically significant 
reduction of 85% in the risk of the composite out-
come of symptomatic deep-vein thrombosis or 
pulmonary embolism at day 47. The number 
needed to treat to prevent one episode of pulmo-
nary embolism with fondaparinux as compared 
with placebo in the patients with superficial-vein 
thrombosis in our study (300) is similar to the 
number needed to treat with low-molecular-weight 
heparin as compared with placebo or no treatment 
in trials of thromboprophylaxis in acutely ill 
medical patients (345).28 Fondaparinux also re-
duced the risk of symptomatic recurrence of su-
perficial-vein thrombosis and, more important, 
its extension to the saphenofemoral junction — 
a finding that is clinically relevant because such 
extension is considered to increase the risk of 
deep-vein thrombosis and pulmonary embolism, 
thereby prompting escalation of therapy (e.g., to 
full-dose anticoagulation or surgery).1,2,6,8,10,11,14 
In our study, fondaparinux reduced by 81% the rate 
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Figure 1. Kaplan–Meier Estimates of the Probability of the Primary Efficacy Outcome, According to Study Group.
The primary efficacy outcome was a composite of death from any cause, symptomatic pulmonary embolism, symp-
tomatic deep-vein thrombosis, or symptomatic extension to the saphenofemoral junction or symptomatic recur-
rence of superficial-vein thrombosis. Data from patients who were lost to follow-up were censored at the time of the 
last contact. I bars indicate 95% confidence intervals.
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of surgery, primarily ligation of the saphenofem-
oral junction, for superficial-vein thrombosis — 
a prespecified secondary outcome. In addition, 
more patients in the placebo group than in the 
fondaparinux group required therapeutic doses 
of anticoagulant therapy.
A potential limitation of our study is the dif-
ficulty in applying the data to clinical practice, 
because a complete ultrasonographic examination 
was performed in every patient with a suspected 
superficial-vein thrombosis — first, to confirm 
the condition, and second, to rule out the pres-
ence of deep-vein thrombosis. However, perform-
ing a complete ultrasonographic examination may 
help physicians avoid treating patients who do 
not have thrombosis and allow the appropriate 
0.50.20.10.050.02 1.0 5.02.0
Placebo BetterFondaparinux Better
Age
<65 yr
65–75 yr
>75 yr
Sex
Male
Female
Weight
<50 kg
50–100 kg
>100 kg
Body-mass index
<30
≥30
Creatinine clearance
<50 ml/min
50–80 ml/min
>80 ml/min
History of deep-vein thrombosis
or pulmonary embolism
Yes
No
History of superficial-vein thrombosis
Yes
No
History of cancer
Yes
No
Varicose veins at inclusion
Yes
No
Superficial-vein thrombosis location
relative to the knee
Above
Below only
Superficial-vein thrombosis involving
great saphenous vein
Yes
No
Distance of thrombus from sapheno-
femoral junction
<10 cm
≥10 cm
Overall
Fondaparinux
no. of events/no. of patients (%)
Hazard Ratio (95% CI)PlaceboSubgroup
61/1033 (5.9)
17/353 (4.8)
10/114 (8.8)
29/556 (5.2)
59/944 (6.3)
  0/1 (0.0)
73/1315 (5.6)
15/181 (8.3)
52/961 (5.4)
36/536 (6.2)
  7/64 (10.9)
24/438 (5.5)
57/984 (5.8)
10/104 (9.6)
78/1396 (5.6)
15/178 (8.4)
73/1322 (5.5)
  0/29 (0.0)
88/1471 (6.0)
76/1329 (5.7)
12/171 (7.0)
49/694 (7.1)
39/806 (4.8)
87/1382 (6.3)
  1/118 (0.8)
17/119 (14.3)
62/1235 (5.0)
88/1500 (5.9)
0.18 (0.10–0.35)
0.18 (0.09–0.34)
0.06 (0.01–0.44)
ND
0.10 (0.04–0.25)
0.25 (0.07–0.87)
0.13 (0.07–0.25)
0.14 (0.08–0.25)
ND
0.15 (0.08–0.28)
0.10 (0.01–0.76)
ND
0.18 (0.10–0.32)
0.21 (0.10–0.44)
0.15 (0.08–0.26)
0.15 (0.08–0.26)
0.15 (0.08–0.31)
ND
0.18 (0.06–0.51)
0.16 (0.07–0.37)
0.14 (0.06–0.31)
0.20 (0.06–0.67)
0.14 (0.07–0.27)
ND
0.12 (0.05–0.25)
0.22 (0.09–0.52)
0.10 (0.01–0.77)
0.01
0.06 (0.01–0.41)
11/1031 (1.1)
1/375 (0.3)
1/114 (0.9)
6/528 (1.1)
7/974 (0.7)
0/2 (0.0)   
10/1313 (0.8)
3/183 (1.6)
7/922 (0.8)
6/574 (1.0)
0/68 (0.0) 
4/412 (1.0)
  9/1007 (0.9)
1/105 (1.0)
12/1397 (0.9)
0/178 (0.0)
13/1324 (1.0)
1/32  (3.1)
12/1470 (0.8)
10/1331 (0.8)
3/171 (1.8)
5/710 (0.7)
8/791 (1.0)
13/1399 (0.9)
0/103 (0.0)
1/117 (0.9)
11/1235 (0.9)
13/1502 (0.9)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF DEBRECEN on March 30, 2011. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Fondaparinux for Superficial-Vein Thrombosis
n engl j med 363;13 nejm.org september 23, 2010 1231
care of patients who present with concomitant 
deep-vein thrombosis.8 Our results were obtained 
without the use of repeat systematic compression 
ultrasonography — in contrast to clinical practice 
in certain countries.8 The 45-day regimen of sub-
cutaneous injections could also be questioned 
from a practical standpoint. However, the feasi-
bility of such treatment was confirmed by the high 
degree of patient adherence; more than 90% of 
patients injected themselves with the study drug. 
The effect of the 45-day fondaparinux regimen on 
the quality of life was not formally assessed in our 
study. However, the significantly reduced risk of 
symptomatic complications and of recourse to 
surgery or therapeutic doses of anticoagulant 
agents that we observed with fondaparinux ther-
apy is likely to be associated with an improved 
quality of life. Finally, the cost-effectiveness of a 
45-day regimen of fondaparinux remains to be 
evaluated, taking into account the clinical events 
that may be prevented with treatment and factors 
that potentially vary across countries, such as the 
direct cost of fondaparinux and the clinical man-
agement (including diagnostic and therapeutic 
procedures) that is currently proposed in routine 
practice when fondaparinux is not used.
In conclusion, patients with isolated, symptom-
atic superficial-vein thrombosis in the legs are at 
substantial risk for symptomatic thromboembo-
lic complications. Fondaparinux administered at 
a dose of 2.5 mg once daily for 45 days is effec-
tive and widely applicable for the treatment of 
such patients.
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Table 4. Safety Outcomes up to Day 47.
Safety Outcome
Fondaparinux 
(N = 1499)
Placebo 
(N = 1488)
no. with event (%)
Bleeding
Major* 1 (0.1) 1 (0.1)
Fatal 0 0
Symptomatic in a critical organ† 1 (0.1) 0
Causing 2 g/dl fall in hemoglobin or neces-
sitating transfusion of ≥2 units of 
packed red cells or whole blood‡
0 1 (0.1)
Clinically relevant nonmajor 5 (0.3) 8 (0.5)
Minor 9 (0.6) 6 (0.4)
Any 15 (1.0) 14 (0.9)
Arterial thromboembolic complication§ 0 3 (0.2)
Any adverse event 195 (13.0) 199 (13.4)
Drug-related 56 (3.7) 49 (3.3)
Nonfatal serious 10 (0.7) 16 (1.1)
Leading to discontinuation of study treatment 18 (1.2) 29 (1.9)
Leading to withdrawal from study 2 (0.1) 1 (0.1)
* P = 1.00 with the use of Fisher’s exact test.
† One patient in the fondaparinux group had retinal bleeding that resolved after 
the discontinuation of study treatment; there were no functional consequences 
that affected vision.
‡ One patient in the placebo group had epistaxis that necessitated medical in-
tervention but that resolved without further consequences.
§  There were two cases of acute coronary syndrome and one of ischemic stroke 
— all in the placebo group.
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